

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2025 (Unaudited) USD Dollars	March 31, 2024 (Unaudited) USD Dollars
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 649,925,814	\$ 318,784,382
Short-term bank deposits	-	31,447,079
Marketable securities	307,141,469	390,428,886
Trade accounts receivable	28,654,011	30,463,622
Other receivables and prepaid expenses:		
Prepaid expenses	1,189,348	2,062,306
Deferred income taxes	-	-
Government authorities	434,051	601,864
Advances to suppliers	321,677	241,865
Derivative instruments	-	-
Intercompany balances and Loan	361,469,826	340,940,534
Other	7,101,130	9,572,192
TOTAL Other receivables and prepaid expenses	<u>370,516,031</u>	<u>353,418,761</u>
Inventories	<u>82,482,025</u>	<u>76,527,903</u>
TOTAL CURRENT ASSETS	1,438,719,350	1,201,070,635
LONG-TERM RECEIVABLES AND OTHER ASSETS	232,247,290	376,359,212
FIXED ASSETS:		
Cost	140,934,119	166,335,719
Less - accumulated depreciation	<u>(56,477,355)</u>	<u>(79,819,462)</u>
	84,456,764	86,516,257
GOODWILL	276,147	276,147
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	47,728,786	58,367,192
INVESTMENT IN ASSOCIATED COMPANIES	392,740,268	372,600,002
INVESTMENT IN PARTNERSHIPS	3,500,000	3,500,000
DEFERRED INCOME TAXES	2,867,334	2,516,918
TOTAL ASSETS	<u>\$ 2,202,535,939</u>	<u>\$ 2,101,206,362</u>

BALANCE SHEETS

	<u>March 31, 2025</u>	<u>March 31, 2024</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	<u>USD Dollars</u>	<u>USD Dollars</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ 23,147,724	\$ 19,648,503
Other current liabilities:		
Returns reserve	9,244,666	7,694,673
Due to customers	-	-
Intercompany balances	1,401,664	42,974
Employees and payroll accruals	7,029,565	5,756,520
Deferred revenue	174,539	236,624
Medicaid and indirect rebates	7,458,856	6,403,136
Accrued income taxes	5,486,228	1,665,574
Legal and audit fees	-	-
Accrued expenses	10,709,056	17,275,214
Interest payable	-	-
Derivative instruments	-	-
Deferred taxes	-	-
Other	162,619	293,874
TOTAL Other current liabilities	<u>41,667,193</u>	<u>39,368,588</u>
TOTAL CURRENT LIABILITIES	<u>64,814,917</u>	<u>59,017,091</u>
LONG-TERM LIABILITIES:		
Deferred income taxes	-	-
Other long-term liabilities	1,490,804	1,876,930
	<u>1,490,804</u>	<u>1,876,930</u>
SHAREHOLDERS' EQUITY	<u>2,136,230,218</u>	<u>2,040,312,341</u>
	<u>\$ 2,202,535,939</u>	<u>\$ 2,101,206,362</u>

Date of approval of the
financial statements

Jeremy James
Director, Finance

STATEMENTS OF INCOME

	For the year Ended March 31, 2025 (Unaudited) USD Dollars	For the year Ended March 31, 2024 (Unaudited) USD Dollars
Sales	\$ 284,203,417	\$ 312,859,580
Cost of sales	<u>185,893,164</u>	<u>184,560,395</u>
Gross profit	98,310,252	128,299,185
Research and development	19,848,459	27,948,387
Selling and marketing expenses	17,513,137	17,999,356
General and administrative expenses	<u>6,509,970</u>	<u>8,392,108</u>
Operating income	54,438,685	73,959,333
Settlements and Loss Contingencies	-	-
Financing income (expenses), net	62,169,381	55,650,532
Other income (expense)	<u>1,771,680</u>	<u>1,259,040</u>
Income before taxes on income	118,379,747	130,868,905
Taxes on income	<u>27,011,318</u>	<u>23,823,131</u>
Net income for the period before subsidiaries and dividen	91,368,428	107,045,773
Dividend income, net	-	-
Subsidiaries	<u>-</u>	<u>-</u>
Net income for the period	<u>\$ 91,368,428</u>	<u>\$ 107,045,773</u>

TARO PHARMACEUTICALS INC.

Changes in Shareholders' Equity

USD Dollars

Unaudited

	Number of Shares (Unaudited)	Share Capital (Unaudited)	Additional Paid-in Capital (Unaudited)	Accumulated Other Comprehensive Income (Loss) (Unaudited)	Foreign Currency Translation Adj (Unaudited)	Retained Earnings (Unaudited)	Total Taro Shareholders' Equity (Unaudited)	Noncontrolling Interest (Unaudited)	Total Shareholders' Equity (Unaudited)
Balance at March 31, 2023 (USD)	12	372,607,244	263,098	(9,353,002)	(156,753,284)	1,721,501,416	1,928,265,472	-	1,928,265,472
Comprehensive income, net of tax	-	-	-	5,001,095	-	-	5,001,095	-	5,001,095
Net income (loss)	-	-	-	-	-	107,045,773	107,045,773.00	-	107,045,773
Balance at March 31, 2024 (USD)	12	372,607,244	263,098	(4,351,906)	(156,753,284)	1,828,547,189	2,040,312,341	-	2,040,312,341
Comprehensive income, net of tax	-	-	-	4,549,450	-	-	4,549,450	-	4,549,450
Net income (loss)	-	-	-	-	-	91,368,428	91,368,428	-	91,368,428
Balance at March 31, 2025 (USD)	12	372,607,244	263,098	197,543	(156,753,284)	1,919,915,617	2,136,230,218	-	2,136,230,218